JP Morgan Private Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $18.3M | Buy |
52,516
+18,726
| +55% | +$6.55M | 0.05% | 285 |
|
|
2023
Q2 | $11.9M | Sell |
33,790
-4,386
| -11% | -$1.48M | 0.06% | 211 |
|
|
2023
Q1 | $12M | Sell |
38,176
-2,142
| -5% | -$642K | 0.03% | 394 |
|
|
2022
Q4 | $11.6M | Sell |
40,318
-3,842
| -9% | -$1.17M | 0.03% | 394 |
|
|
2022
Q3 | $12.8M | Buy |
44,160
+12,826
| +41% | +$3.69M | 0.03% | 347 |
|
|
2022
Q2 | $8.83M | Sell |
31,334
-1,772
| -5% | -$474K | 0.02% | 431 |
|
|
2022
Q1 | $8.64M | Buy |
33,106
+2,674
| +9% | +$635K | 0.02% | 474 |
|
|
2021
Q4 | $6.68M | Buy |
30,432
+23,254
| +324% | +$4.52M | 0.01% | 538 |
|
|
2021
Q3 | $1.3M | Buy |
7,178
+1,561
| +28% | +$305K | ﹤0.01% | 1085 |
|
|
2021
Q2 | $1.13M | Buy |
5,617
+1,443
| +35% | +$302K | ﹤0.01% | 1139 |
|
|
2021
Q1 | $897K | Sell |
4,174
-1,319
| -24% | -$290K | ﹤0.01% | 1092 |
|
|
2020
Q4 | $1.3M | Sell |
5,493
-20,852
| -79% | -$4.78M | ﹤0.01% | 902 |
|
|
2020
Q3 | $7.17M | Buy |
26,345
+21,039
| +397% | +$5.8M | 0.03% | 382 |
|
|
2020
Q2 | $1.54M | Buy |
5,306
+282
| +6% | +$76.5K | 0.01% | 657 |
|
|
2020
Q1 | $1.2M | Sell |
5,024
-752
| -13% | -$173K | 0.01% | 658 |
|
|
2019
Q4 | $1.26M | Sell |
5,776
-2,848
| -33% | -$576K | 0.01% | 715 |
|
|
2019
Q3 | $1.46M | Sell |
8,624
-2,133
| -20% | -$377K | 0.01% | 649 |
|
|
2019
Q2 | $1.97M | Sell |
10,757
-9,617
| -47% | -$1.68M | 0.01% | 592 |
|
|
2019
Q1 | $3.75M | Sell |
20,374
-439
| -2% | -$81.1K | 0.02% | 471 |
|
|
2018
Q4 | $3.45M | Buy |
20,813
+6,234
| +43% | +$1.08M | 0.02% | 442 |
|
|
2018
Q3 | $2.81M | Sell |
14,579
-139
| -0.9% | -$24.8K | 0.01% | 556 |
|
|
2018
Q2 | $2.5M | Buy |
14,718
+2,932
| +25% | +$454K | 0.01% | 553 |
|
|
2018
Q1 | $1.92M | Buy |
11,786
+309
| +3% | +$50.5K | 0.01% | 494 |
|
|
2017
Q4 | $1.72M | Sell |
11,477
-1,166
| -9% | -$173K | 0.01% | 521 |
|
|
2017
Q3 | $1.92M | Buy |
12,643
+346
| +3% | +$52.1K | 0.01% | 476 |
|
|
2017
Q2 | $1.58M | Buy |
12,297
+503
| +4% | +$60.5K | 0.01% | 511 |
|
|
2017
Q1 | $1.29M | Sell |
11,794
-5,125
| -30% | -$451K | 0.01% | 563 |
|
|
2016
Q4 | $1.25M | Buy |
16,919
+19
| +0.1% | +$1.55K | 0.01% | 540 |
|
|
2016
Q3 | $1.47M | Sell |
16,900
-684
| -4% | -$64.6K | 0.01% | 508 |
|
|
2016
Q2 | $1.51M | Buy |
17,584
+5,741
| +48% | +$496K | 0.01% | 500 |
|
|
2016
Q1 | $941K | Sell |
11,843
-868
| -7% | -$78.5K | 0.01% | 574 |
|
|
2015
Q4 | $1.6M | Buy |
12,711
+564
| +5% | +$68.1K | 0.02% | 417 |
|
|
2015
Q3 | $1.26M | Sell |
12,147
-3,680
| -23% | -$473K | 0.02% | 422 |
|
|
2015
Q2 | $1.95M | Sell |
15,827
-68
| -0.4% | -$8.57K | 0.02% | 372 |
|
|
2015
Q1 | $1.88M | Buy |
15,895
+722
| +5% | +$86.5K | 0.02% | 390 |
|
|
2014
Q4 | $1.8M | Buy |
15,173
+1,595
| +12% | +$180K | 0.02% | 400 |
|
|
2014
Q3 | $1.52M | Buy |
13,578
+4,338
| +47% | +$413K | 0.02% | 417 |
|
|
2014
Q2 | $875K | Buy |
9,240
+1,356
| +17% | +$95.1K | 0.01% | 436 |
|
|
2014
Q1 | $558K | Buy |
7,884
+3,289
| +72% | +$260K | 0.01% | 540 |
|
|
2013
Q4 | $341K | Buy |
4,595
+583
| +15% | +$40.6K | 0.01% | 515 |
|
|
2013
Q3 | $304K | Buy |
+4,012
| New | +$319K | 0.01% | 508 |
|
Other funds holding VRTX
JP Morgan Private Wealth Advisors's VRTX Position: Q3 2023 in Review
JP Morgan Private Wealth Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 55% in Q3 2023, buying an estimated $6.55M and bringing the position to 52,516 shares worth $18.3M. The position accounts for 0.05% of the portfolio, ranked #285.
JP Morgan Private Wealth Advisors first reported a position in VRTX in Q3 2013 and has held it in 41 quarters since. 1,278 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.
- JP Morgan Private Wealth Advisors held 52,516 shares of Vertex Pharmaceuticals worth $18.3M as of Q3 2023.
- JP Morgan Private Wealth Advisors bought 18,726 Vertex Pharmaceuticals shares in Q3 2023, an estimated $6.55M.
- Vertex Pharmaceuticals made up 0.05% of JP Morgan Private Wealth Advisors's portfolio in Q3 2023, its #285 holding.
- JP Morgan Private Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 41 quarters since.
- 1,278 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.
Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.